PhereSys(TM) Therapeutics Appoints John Ball, MD, as Its Midwest Regional Medical Director.EL DORADO HILLS, Calif. -- PhereSys Therapeutics Corporation ("PhereSys") announced today that John Ball, MD, has joined PhereSys Therapeutics as its Midwest Regional Medical Director. Dr. Ball graduated from the George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. School of Medicine and was the Clinical Assistant Professor of Medicine at the University of Illinois at Chicago This article is about the University of Illinois at Chicago. For other uses, see University of Illinois at Chicago (disambiguation). UIC participates in NCAA Division I Horizon League competition as the UIC Flames in several sports, most notably Basketball. before assuming his current positions as Medical Director at Logan Square Dialysis and Chief, Section of Nephrology nephrology Branch of medicine dealing with kidney function and diseases. An understanding of kidney physiology is important not only in treating kidney disease but in knowing the effect of drugs, diet, and hypertension on kidney disease, and vice versa. , at the Illinois Masonic Medical Center in Chicago. He has over 25 years' experience in the fields of nephrology and therapeutic apheresis therapeutic apheresis A form of exchange transfusion in which blood is removed from a Pt and fluids returned to the general circulation: 1. Plasma is replaced–plasmapheresis with a volume of albumin or a crystalloid solution. 2. , and has published numerous scientific articles. Dr. Ball is board certified by the National Board of Medical Examiners, the American Board of Internal Medicine The American Board of Internal Medicine (ABIM) is a non-profit, independent physician organization in the U.S. that certifies physicians who practice in internal medicine and its sub-specialties. and the American Board of Nephrology. Richard Davis, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of PhereSys Therapeutics, stated: "We are fortunate that Dr. Ball has accepted the position as our Midwest Regional Medical Director. Dr. Ball's extensive academic and practical experience will be instrumental in our development of innovative methods of delivering therapeutic apheresis services to hospitals and physician practices. Such methods now include the establishment of PhereSys Centers of America(TM) specialty clinics -- where patients can obtain convenient, cost-effective apheresis apheresis (əfĕr`əsĭs), or hemapheresis (hē'məfĕr`əsĭs), any procedure in which blood is drawn from a donor or patient and a component (platelets, plasma, or white blood treatments, and where participating physicians' practices can expand their therapeutic armamentarium ar·ma·men·tar·i·um n. pl. ar·ma·men·tar·i·ums or ar·ma·men·tar·i·a The complete equipment of a physician or medical institution, including drugs, books, supplies, and instruments. while adding a new source of revenue." About PhereSys Therapeutics Corporation PhereSys Therapeutics (www.pheresys.com) is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. founded to become the premier therapeutic apheresis and cellular therapies provider in the United States. Therapeutic apheresis, or "blood filtering," is a medical procedure where whole blood is separated into its components in order to remove disease-causing substances for therapeutic purposes. The Company currently provides its services to hospitals and physicians' offices in California and New York. PhereSys is scaling up an aggressive nationwide expansion of its business model with new initiatives now underway in Minnesota, Illinois and Texas. At least 10 other states are scheduled for operations in the coming year. PhereSys' strategy involves establishing a nationwide network of fully licensed and certified apheresis and cellular therapy alternate-site clinics which will serve to anchor its mobile business as well as consolidate its strategic relationships with hospitals, TA providers and blood banks. In addition, select facilities will be designated as "PhereSys Centers of America" to assist promising TA technology companies and pharmaceutical and biotech companies in pursuit of clinical trials and to further the development and commercialization of their TA, stem cell and other advanced cellular therapies. Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may vary. We do not undertake to update any forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion